Since 2023, I have been a researcher at the Laboratory of Cellular Basis of Behavior and Disease with Dr. Edgar Soria-Gómez, within the IKUR Strategy initiative. My current work explores how CB1 signaling shapes prefrontal and hippocampal circuits in both health and psychiatric disorders, using cutting-edge tools such as in vivo calcium imaging in freely moving animals combined with behavioral analysis.

Throughout my career, I have focused on neurodevelopmental and neurodegenerative disorders, approaching them from multiple angles — from postnatal brain development and cannabinoid signaling to responses to acute and chronic insults and their behavioral consequences. I obtained my Ph.D. in Biomedical Research from the Complutense University of Madrid in 2019, where I investigated the neuroprotective effects of cannabidiol in neonatal hypoxia-ischemia and its long-term impact on adult behavior. This work was enriched by research stays in San Francisco, Rome, and Birmingham.

As a postdoctoral researcher, I first joined the Institute of Neuroscience in Montpellier, studying neuron–glia interactions in Multiple Sclerosis under the guidance of Dr. Nicolas Tricaud with support from the ARSEP Foundation. There, I examined the metabolic role of astrocytes and its connection to motor deficits and disease progression. Later, at the NeuroMyoGène Institute in Lyon, I worked on a gene therapy project for Giant Axon Neuropathy, a rare neurodevelopmental disorder. My studies combined behavioral analyses from early postnatal stages to adulthood with sex-specific approaches and detailed profiling of brain and spinal cord development.

Beyond research, I am committed to science communication, patient advocacy, and mentoring, driven by the conviction that scientific discovery should always connect with real-world impact.